Építés alatt – nem éles oldal
Belépés
Fut, nem toboroz2. fázis

Metyrapone for Mild Autonomous Cortisol Secretion (MACS)

A legfontosabb adatok

Ki végzi
Mayo Clinic
Hol
Rochester (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Fut, nem toboroz
Fázis
2. fázis
Résztvevők
30 fő, tervezett
Kezdés
2023. dec. 19.
Várható befejezés
2028. febr. 1.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Metyrapone
A regiszteradat frissítve
2026. szeptember 25.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 21 feltétel megnézéseKevesebb

Ki vehet részt

  • Provide written informed consent
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Diagnosed with MACS: at least 2 abnormal post-dexamethasone cortisol results (1 mg post-dexamethasone cortisol > 1.8 mcg/d; or 8 mg post-dexamethasone cortisol > 1 mcg/dL) and historical dexamethasone suppression test results can be used if performed within 24 months prior to enrollment
  • Adrenal imaging phenotype consistent with benign disease (adrenal adenoma/s, macronodular or micronodular adrenal hyperplasia)
  • At least one of the following comorbidities: obesity (BMI > 30 kg/m\^2); dysglycemia; dyslipidemia; hypertension; osteopenia; osteoporosis; fragility fractures
  • Ability to take oral medication and be willing to adhere to the study intervention regimen
  • For females of reproductive potential: use of highly effective contraception initiated prior to baseline visit and for 1 month after completing metyrapone study
  • For persons of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use a contraceptive method with a failure rate of <5% per year during the treatment period and for 6 months after the last dose of study treatment
  • Stable timing for bedtime for at least one week prior to on-site study visits

Ki nem vehet részt

  • Planned alternative therapy for MACS within 6 months after joining the study
  • Current use of oral exogenous glucocorticoid therapy
  • Current use of opioid therapy > 20 MME/day
  • Planned use of oral exogenous glucocorticoid therapy
  • Planned use of opioid therapy > 20 MME/day
  • Investigator's judgement based on history/physical examination that a comorbidity or concomitant medication may impact the hypothalamic-pituitary-adrenal axis or steroid metabolome
  • Suspected false positive post-dexamethasone cortisol results due to increased metabolism, poor absorption, or noncompliance with dexamethasone
  • Treatment with another investigational drug or other intervention within lower than specific therapy washout period
  • Uncontrolled intercurrent illness including, but not limited to: ongoing or active infection; symptomatic congestive heart failure; unstable angina pectoris; cardiac arrhythmia; psychiatric illness/social situations that would limit compliance with study requirements
  • Known allergic reactions to metyrapone
  • Use of injectable glucocorticoid within the last 6 weeks
  • Pregnancy or lactation

Helyszínek itt: Egyesült Államok

  • Mayo Clinic MinnesotaRochester, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

The purpose of this study is to find out whether the study drug, metyrapone, is safe and effective in treating participants with Mild Autonomous Cortisol Secretion (MACS).

A vizsgálat csoportja

  • Mild Autonomous Cortisol Secretion (MACS) Open Label Phase and Optional Extension PhaseA vizsgált kezelés

    Subjects diagnosed with Mild Autonomous Cortisol Secretion (MACS) will receive metyrapone for a 6 month treatment period (Open Label Phase) with the option to continue for an additional 30 months of metyrapone therapy. If a patient chooses to participate in the Optional Extension Phase they will continue to receive metyrapone therapy until Month 36. This is an additional 30 months of therapy after completion of the Open Label Phase.

    Kezelés: Metyrapone

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Metyrapone Intervention in Patients With Mild Autonomous Cortisol Secretion (MACS)
A regiszteradat frissítve
2026. szeptember 25.